Literature DB >> 10755644

Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain.

J Logan1, J S Fowler, N D Volkow, G J Wang, R R MacGregor, C Shea.   

Abstract

The purpose of this study was to assess the reproducibility of repeated positron emission tomography (PET) measures of brain monoamine oxidase B (MAO B) using deuterium-substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) in normal subjects and to validate the method used for estimating the kinetic constants from the irreversible 3-compartment model applied to the tracer binding. Five normal healthy subjects (age range 23-73 years) each received two PET scans with [11C]L-deprenyl-D2. The time interval between scans was 7-27 days. Time-activity data from eight regions of interest and an arterial plasma input function was used to calculate lambda k3, a model term proportional to MAO B, and K1, the plasma to brain transfer constant that is related to blood flow. Linear (LIN) and nonlinear least-squares (NLLSQ) estimation methods were used to calculate the optimum model constants. A comparison of time-activity curves for scan 1 and scan 2 showed that the percent of change for peak uptake varied from -18.5 to 15.0% and that increases and decreases in uptake on scan 2 were associated with increases and decreases in the value of the arterial input of the tracer. Calculation of lambda k3 showed a difference between scan 1 and scan 2 in the global value ranging between -6.97 and 4.5% (average -2.1 +/- 4.7%). The average percent change for eight brain regions for the five subjects was -2.84 +/- 7.07%. Values of lambda k3 for scan 1 and scan 2 were highly correlated (r2 = 0.98; p < 0.0001; slope 0.955). Similarly, values of K1 showed a significant correlation between scan 1 and scan 2 (r2 = 0.61; p < 0.0001; slope 0.638) though the values for scan 2 were generally lower than those of scan 1. There was essentially no difference between the values of model constants calculated using the NLLSQ or LIN methods. Regional brain uptake of [11C]L-deprenyl-D2 varied between scan 1 and scan 2, driven by the differences in arterial tracer input. Application of a 3-compartment model to regional time-activity data and arterial input function yielded lambda k3 values for scan 1 and scan 2 with an average difference of -2.84 +/- 7.07%. Linear regression applied to values of lambda k3 from the LIN and NLLSQ methods validated the use of the linear method for calculating lambda k3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755644     DOI: 10.1016/s0969-8051(99)00088-8

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  10 in total

Review 1.  Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Gene-Jack Wang
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

Review 2.  Modeling of PET data in CNS drug discovery and development.

Authors:  Katarina Varnäs; Andrea Varrone; Lars Farde
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-05-10       Impact factor: 2.745

3.  [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation.

Authors:  Fang Xie; Weijun Wei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10       Impact factor: 10.057

4.  Kinetic modeling of the monoamine oxidase B radioligand [¹¹C]SL25.1188 in human brain with high-resolution positron emission tomography.

Authors:  Pablo M Rusjan; Alan A Wilson; Laura Miler; Ian Fan; Romina Mizrahi; Sylvain Houle; Neil Vasdev; Jeffrey H Meyer
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

5.  Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation.

Authors:  Daniel S Albrecht; Anton Forsberg; Angelica Sandström; Courtney Bergan; Diana Kadetoff; Ekaterina Protsenko; Jon Lampa; Yvonne C Lee; Caroline Olgart Höglund; Ciprian Catana; Simon Cervenka; Oluwaseun Akeju; Mats Lekander; George Cohen; Christer Halldin; Norman Taylor; Minhae Kim; Jacob M Hooker; Robert R Edwards; Vitaly Napadow; Eva Kosek; Marco L Loggia
Journal:  Brain Behav Immun       Date:  2018-09-14       Impact factor: 7.217

6.  Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo.

Authors:  Katarina Varnäs; Sjoerd J Finnema; Peter Johnström; Ryosuke Arakawa; Christer Halldin; Lars I Eriksson; Lars Farde
Journal:  Br J Anaesth       Date:  2020-10-06       Impact factor: 9.166

7.  Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Authors:  Stefan Sturm; Anton Forsberg; Stephane Nave; Per Stenkrona; Nicholas Seneca; Andrea Varrone; Robert A Comley; Patrik Fazio; Candice Jamois; Ryuji Nakao; Zbigniew Ejduk; Nabil Al-Tawil; Ulrika Akenine; Christer Halldin; Niels Andreasen; Benedicte Ricci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-16       Impact factor: 9.236

8.  Test-retest reproducibility of [11C]-L-deprenyl-D2 binding to MAO-B in the human brain.

Authors:  Ryosuke Arakawa; Per Stenkrona; Akihiro Takano; Sangram Nag; Rafael S Maior; Christer Halldin
Journal:  EJNMMI Res       Date:  2017-06-20       Impact factor: 3.138

9.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.

Authors:  Kok Pin Ng; Tharick A Pascoal; Sulantha Mathotaarachchi; Joseph Therriault; Min Su Kang; Monica Shin; Marie-Christine Guiot; Qi Guo; Ryuichi Harada; Robert A Comley; Gassan Massarweh; Jean-Paul Soucy; Nobuyuki Okamura; Serge Gauthier; Pedro Rosa-Neto
Journal:  Alzheimers Res Ther       Date:  2017-03-31       Impact factor: 6.982

10.  A New Highly Deuterated [18F]AV-45, [18F]D15FSP, for Imaging β-Amyloid Plaques in the Brain.

Authors:  Hao Xiao; Seok Rye Choi; Ruiyue Zhao; Karl Ploessl; David Alexoff; Lin Zhu; Zhihao Zha; Hank F Kung
Journal:  ACS Med Chem Lett       Date:  2021-06-21       Impact factor: 4.632

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.